Amplia Therapeutics Limited (ASX:ATX)
0.0780
-0.0030 (-3.70%)
Oct 22, 2026, 4:10 PM AEDT
Amplia Therapeutics Revenue
In the fiscal year ending March 31, 2026, Amplia Therapeutics had annual revenue of 4.79M AUD with 26.63% growth. Amplia Therapeutics had revenue of 2.16M in the half year ending March 31, 2026, with 7.80% growth. That makes Amplia Therapeutics the 41,139th largest company in the world by revenue and 809th in Australia.
Revenue
4.79M
Revenue Growth
+26.63%
P/S Ratio
8.68
Revenue / Employee
n/a
Employees
n/a
Market Cap
40.04M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.79M | 1.01M | 26.63% |
| Mar 31, 2025 | 3.78M | -669.04K | -15.03% |
| Mar 31, 2024 | 4.45M | 3.26M | 274.34% |
| Mar 31, 2023 | 1.19M | -793.83K | -40.03% |
| Mar 31, 2022 | 1.98M | 449.80K | 29.33% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Botanix Pharmaceuticals | 33.80M |
| Immutep | 19.93M |
| Neurizon Therapeutics | 17.59M |
| Neurotech International | 4.73M |
| Alterity Therapeutics | 3.61M |
| Arovella Therapeutics | 3.50M |
| Prescient Therapeutics | 3.45M |
| Entropy Neurodynamics | 1.91M |
Amplia Therapeutics News
- 2 months ago - Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly's Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer - GlobeNewsWire
- 2 months ago - Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online - GlobeNewsWire
- 3 months ago - Amplia Announces Publication of New FAK Inhibitor Patent Application - GlobeNewsWire
- 3 months ago - Amplia Announces Appointment of Brett Carter to Board - GlobeNewsWire
- 3 months ago - Amplia Announces Changes to Board's Leadership Roles - GlobeNewsWire
- 4 months ago - Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer - GlobeNewsWire
- 5 months ago - Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib - GlobeNewsWire
- 5 months ago - Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study - GlobeNewsWire